 |
|
Subject: an additional year of data and market exclusivity med. In 2011 the European Commission granted marketing authorization for XGEVA for the prevention of skeletal-related events in adults with... and it also granted an additional year of data and market exclusivity in the European Unit since the indication was considered new and based on the significant clinical benefit of XGEVA in comparison with existing therapies....предоставила еще один [дополнительно один] год для ... |
| продлили им чо-та-там на год |
|
exclusivity эксклюзивные права на год проталкивать свою продукцию. |
| You need to be logged in to post in the forum |